'First' stem cell treatment approved in Canada
This article was originally published in Scrip
Executive Summary
Osiris Therapeutics' Prochymal (remestemcel-L) for treating acute graft-vs-host disease (GvHD) has become the world's first manufactured stem cell therapy to win regulatory approval, claims the firm. Health Canada has approved the product for managing acute GvHD in children who fail to respond to steroids.